AMRX יחס מהיר Amneal Pharmaceuticals

Amneal Pharmaceuticals (AMRX) develops generics and biosimilars, combating price erosion through the release of complex injectables. Fluctuations in the quick ratio on this chart show that the metric has reached 1.48, confirming the company's ability to settle debts without selling off inventory. However, pressure in the core segment and FDA delays are creating challenges. Additionally, debt load and potential product quality claims are limiting financial flexibility.

For Amneal Pharmaceuticals (AMRX), with its extensive manufacturing network in the US and India, this quick ratio reflects the ability to cover obligations without relying on slow-moving drug inventories. The metric aggregates cash and accounts receivable, allowing investors to assess the actual reserve of liquid capital and avoid overpaying for excessive non-performing assets that reduce overall stock returns.